Mechanistic studies have further revealed that venetoclax may potentiate T-cell anti-leukemic activity via PD-1/PD-L1 pathway downregulation, while HMAs enhance tumor antigen presentation through epigenetic modulation (12). Here, CD274 is linked to neoplasm.